The largest shareholder of Aptahem suggests Dr Bert Junno as the new Chairman of the Board
Aptahem AB (publ), announce today that the company’s largest shareholder, Ivar Nordqvist, suggests Dr Bert Junno to be elected new Chairman of the Board at the coming Extraordinary General Meeting on 25 September 2020. This after the former Chairman of the Board, Dr Kjell G Stenberg, requested his own resignation.
Dr Junno, born in 1966, is currently the Chairman of the Board of Cyxone AB (publ) and CombiGene AB (publ) and board member of Accequa AB and Accequa GmbH. He has previous management and board level experience from several European and US based companies in fields of electronics, biotech and IT. He has also co-founded several life science companies, for example WntResearch AB (publ), Galecto Biotech AB, Gabather AB (publ), Aptahem AB (publ) and Cyxone AB (publ). Dr Junno holds a Ph.D. in Semiconductor Physics and Technology and a M.Sc. in Physics from Lund University. Dr Junno does not hold any shares in Aptahem.
”Bert Junno is probably well known for those close to Aptahem, for example as a previous member of the board. His long experience from several board assignments and his solid knowledge in IP and partnering in research based small companies makes him well suited to lead the Board of Directors in the next phase of Aptahem’s development” comments Ivar Nordqvist.
For further information:
Mikael Lindstam, CEO
Tel: +46 (0)766-33 36 99
This information was provided through the agency of the contact person above, for publication on 17 September 2020.
Aptahem AB (APTA) is a biotechnology company that develops aptamer-based pharmaceuticals for the treatment of life-threatening conditions in which a combination of coagulation and inflammation are involved. The company’s primary pharmaceutical candidate, Apta-1, is being developed with the aim of preventing the high mortality rate caused by organ and tissue damage in sepsis patients, among others. The company possesses patent protection in strategic target markets and actively seeks business development opportunities with potential collaborators.